source
- GSK to acquire cancer-focused biotech Nuvalent for $10.6 billionGSK announced it will acquire Nuvalent, a biotech that develops targeted cancer therapies, in a transaction valued at $10.6 billion. The purchase price translates to $124 per Nuvalent share, a 26%…
- FDA adds bemotrizinol, first new sunscreen ingredient in 20 yearsThe U.S. Food and Drug Administration has approved bemotrizinol as a new active ingredient for over‑the‑counter sunscreens, marking the first addition to the sunscreen monograph since the late 1990…